Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Rapid7, a leader in extended risk and threat detection, today announced its financial results for the fourth quarter and full-year 2024.
-
FDA awards ConSynance's CSTI-500 Rare Pediatric Disease Designation for innovative Prader-Willi Syndrome treatment.
-
Rapid7 shareholders are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
-
Rapid7 shareholders are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
-
Rapid7 shareholders are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
-
Rapid7 Investors are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
-
Rapid7 Shareholders are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
-
Rapid7 Shareholders are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
-
Rapid7 Shareholders are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.
-
Rapid7 Shareholders are encouraged to contact BFA Law about its investigation into potential claims for breach of fiduciary duty against Rapid7, Inc.